Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development.

T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.